Results 111 to 120 of about 275,402 (290)
Double hit B-cell lymphomas are rare tumors that are defined by a chromosomal breakpoint affecting the MYC/8q24 locus in combination with another recurrent breakpoint, mainly a t(14;18)(q32;q21) involving BCL2.
Sakshi Kapur, Miles B. Levin
doaj +1 more source
Follicular lymphoma is the second most common sub-type of non-Hodgkin’s lymphoma. Although rarely considered curable, this indolent lymphoma typically follows a remitting and relapsing pattern, often over years.
Horn, Jeff, Campbell, Karen
core +1 more source
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon +14 more
wiley +1 more source
Summary Glofitamab was investigated with obinutuzumab/rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (G/R‐CHOP) in patients with relapsed/refractory B‐cell non‐Hodgkin lymphoma (B‐NHL) who had ≥1 prior obinutuzumab/rituximab‐containing therapy (NCT03467373). The primary end‐point was to determine the optimal biological dose of
William Townsend +16 more
wiley +1 more source
LTB‐TREAT is a validated international prognostic model that identifies three groups of patients with distinct rates of time to treatment (TTT) in low tumour burden follicular lymphoma. The low‐risk group has a prolonged TTT with WW. The high‐risk group has early progression in whom treatment at diagnosis can be considered. Summary Watchful waiting (WW)
Luani Barge +25 more
wiley +1 more source
Primary prostatic lymphoma is an exceedingly rare entity comprising less than 0.09% of all prostatic cancers with follicular lymphoma making up only 12% as a subset.
Shubhneet Bal +5 more
doaj +1 more source
Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
Danielle M Brander, Anne W BeavenDuke University Medical Center, Durham, NC, USAAbstract: Follicular lymphoma is predominantly managed as a chronic disease, with intermittent chemo/immunotherapy reserved for symptomatic progression.
Beaven AW, Brander DM
core
Summary The randomized phase II SAKK 35/14 trial, conducted by the Swiss Group for Clinical Cancer Research (SAKK) and the Nordic Lymphoma Group (NLG), compared efficacy and safety of rituximab (375 mg/m2 intravenously for 4 weeks followed by maintenance every 2 months for 24 months) plus placebo (arm A) versus the same schedule of rituximab plus ...
Maria Cristina Pirosa +25 more
wiley +1 more source
Summary While marginal zone lymphoma (MZL) is generally indolent, outcomes following relapse remain poorly defined. This study utilized the indolent Non Follicular 10 (NF10) prospective database to characterize survival and identify prognostic drivers in patients failing initial systemic therapy. The study analysed 122 patients with relapsed MZL.
Stefano Luminari +28 more
wiley +1 more source
Follicular lymphoma of the duodenum [PDF]
P, Born, M, Vieth, M, Stolte
openaire +2 more sources

